Home > News content

Indonesian government approved the use of China's new crown vaccine: the effectiveness of the test results is 65.3%

via:驱动之家     time:2021/1/12 7:18:56     readed:74

China's R & D speed and marketing speed of new crown vaccine are absolutely in the first echelon in the world, and more and more countries begin to purchase.

According to Indonesian media reports,On January 11, Indonesia's food and Drug Administration approved the emergency use of China Kexing vaccine. The vaccine, produced by a Chinese Biomedical Company, is being tested in the third phase in Bandung, Indonesia, with 1600 volunteers. PANI, head of Indonesia's biopharmaceutical company, said in Jakarta that the effectiveness of the vaccine was 65.3%.

Indonesia's food and Drug Administration announced on the 11th that it approved the urgent use of the new crown vaccine produced by China Kexing Biotechnology Co., Ltd.

Since August last year, China and Indonesia cooperated to carry out the phase III clinical trial of China Kexing Xinguan vaccine in Bandung, Indonesia. Penny said 1600 volunteers participated in the trial and the results showed that the vaccine was 65.3% effective.

The Indonesian government had previously decided to start the nationwide vaccination on the 13th of this month.

A total of 3 million doses of China Kexing finished vaccine were delivered to Indonesia in two batches last month and distributed to all provinces of the country. 15 million doses of semi-finished vaccine will also be delivered to Indonesian vaccine manufacturers this month.

Indonesia officially announced on the afternoon of the 11th that there were 8692 new confirmed cases in Indonesia, with a total of 836718 confirmed cases; 214 new deaths, with a total of 24343 deaths.



Reprint please indicate the source: fast technology

vaccinesNew crown vaccine

China IT News APP

Download China IT News APP

Please rate this news

The average score will be displayed after you score.

Post comment

Do not see clearly? Click for a new code.

User comments